A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis

Journal of the European Academy of Dermatology and Venereology

Volumn 19, Issue 4, 2005, Pages 437-443

  Gupta, A K ^a,b,f   Leonardi, C ^c   Stoltz, R R ^d   Pierce, P F ^e   Conetta, B ^e   Pandya, A ^f   Parish, L ^f   Savin, R ^f   Hebert, A ^f   Scher, R ^f   Morel, P ^f   Drouault, Y ^f  

^a UNIVERSITY OF TORONTO   (Canada)

^b MEDIPROBE RESEARCH INC   (Canada)

^c Hill Top Research Inc   (United States)

^d GFI Pharmaceutical Services Inc   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

^f NONE

Author keywords

Onychomycosis; Ravuconazole; Therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHLORIDE; PLACEBO; POTASSIUM; RAVUCONAZOLE; SODIUM;

ABDOMINAL PAIN; ARTHRALGIA; ARTICLE; CANADA; CLINICAL PRACTICE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENTAL CARIES; DERMATOLOGY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DYSPEPSIA; ERYTHEMA; FLATULENCE; FRANCE; FUNGUS CULTURE; HEADACHE; HUMAN; HYPERCHLOREMIA; HYPERKALEMIA; HYPONATREMIA; INSOMNIA; LIVER DYSFUNCTION; MALAISE; MEDICAL ASSESSMENT; MELENA; MICROSCOPY; MICROSPORUM CANIS; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; TASTE DISORDER; TOENAIL ONYCHOMYCOSIS; TREATMENT OUTCOME; TRICHOPHYTON MENTAGROPHYTES; TRICHOPHYTON RUBRUM; UNITED STATES; UNPLEASANT DREAM; XEROSTOMIA;

ADMINISTRATION, ORAL; ANTIFUNGAL AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FOOT DERMATOSES; FRANCE; HUMANS; NAILS; ONTARIO; ONYCHOMYCOSIS; SEVERITY OF ILLNESS INDEX; THIAZOLES; TREATMENT OUTCOME; TRIAZOLES; UNITED STATES;

EID: 21744456071     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2005.01212.x     Document Type: Article

References (12)

1. Hata K, Kimura J, Miki H et al. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 1996; 40(10): 2243-2247.
2. Fung-Tomc JC, White TC, Minassian B et al. In vitro antifungal activity of BMS-207147 and itraconazole against yeast strains that are nonsusceptible to fluconazole. Diagn Microbiol Infect Dis 1999; 35: 163-167.
3. Moore CB, Walls CM, Denning DW. In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B. Antimicrob Agents Chemother 2000; 44(2): 441-443.
4. Brega EF, Gonzalez G, Fothergill W et al. An in vitro evaluation of new triazole antifungal agents against clinical isolates of dermatophytes in comparison with terbinafine, itraconazole and fluconazole. Abstract 841. Page 23. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, September 17-20, 2000.
5. Grasela DM, Olsen SJ, Mummanen V et al. Ravuconazole: multiple ascending oral dose study in healthy subjects. Abstract 839, Page 22. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada September 17-20, 2000.
6. Mummaneni V, Geraldes M, Hadjilambris OW et al. Effect of ravuconazole on the pharmacokinetics of simvastatin in healthy subjects. Abstract 841, Page 23. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada September 17-20, 2000.
7. Marino MR, Mummaneni V, Norton J et al. Ravuconazole exposure-response relationship in HIV+ patients with oropharyngeal candidiasis. 41st ICAAC. Abstracts. Chicago, Illinois, September 22-25, 2001.
8. Olsen AJ, Rolan P, Mummaneni V et al. Ravuconazole: multiple ascending oral dose study in healthy subjects. Abstract 838. Page 22. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, September 17-20, 2000.
9. Lamisil® (terbinafine hydrochloride tablets) Prescribing Information. 2001. Novartis. Revised October 2001.
10. Sporonox® (itraconazole) capsules - Prescribing Information. 2001. Janssen. Revised January 2003.
11. Pfaller MA, Messer AS, Hollis RJ et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. & other filamentous fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Ag Chemo 2002; 46(4): 1032-1037.
12. National Committee for Clinical Laboratory Standards: Reference Method for Broth Dilution Antifungal Susceptibility Testing for Yeasts, M27-A. January 29, 1997.